Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.96)
# 570
Out of 5,154 analysts
232
Total ratings
45.38%
Success rate
12.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $182.01 | +24.17% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $62.82 | +46.45% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $13.88 | +0.86% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $128.13 | +36.58% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $38.23 | +109.26% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $60.41 | +17.53% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $20.29 | -40.86% | 3 | Dec 8, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $8.68 | +118.89% | 5 | Nov 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $93.52 | +37.94% | 14 | Oct 16, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $61.88 | +27.67% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $15.74 | +77.89% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $15.47 | -87.07% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $5.20 | +150.00% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.34 | +653.14% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $21.25 | +158.82% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.16 | +8.30% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $61.18 | +38.93% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $25.95 | +4.05% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.11 | +751.58% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $3.23 | +23.84% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.80 | +122.22% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $5.33 | +162.66% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.11 | +21.65% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.72 | +10.29% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.21 | +726.45% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $41.55 | -47.05% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.92 | +1,396.98% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.90 | +6,565.19% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.90 | +53.85% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $12.07 | +5,268.68% | 6 | May 8, 2020 |
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $182.01
Upside: +24.17%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $62.82
Upside: +46.45%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $13.88
Upside: +0.86%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $128.13
Upside: +36.58%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $38.23
Upside: +109.26%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $60.41
Upside: +17.53%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $20.29
Upside: -40.86%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $8.68
Upside: +118.89%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $93.52
Upside: +37.94%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $61.88
Upside: +27.67%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $15.74
Upside: +77.89%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $15.47
Upside: -87.07%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $5.20
Upside: +150.00%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.34
Upside: +653.14%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $21.25
Upside: +158.82%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.16
Upside: +8.30%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $61.18
Upside: +38.93%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $25.95
Upside: +4.05%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $4.11
Upside: +751.58%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $3.23
Upside: +23.84%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.80
Upside: +122.22%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $5.33
Upside: +162.66%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.11
Upside: +21.65%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.72
Upside: +10.29%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.21
Upside: +726.45%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $41.55
Upside: -47.05%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.92
Upside: +1,396.98%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.90
Upside: +6,565.19%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.90
Upside: +53.85%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $12.07
Upside: +5,268.68%